Cancer Type: Lymphoma

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email [email protected].

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

Switch to Advanced Search

201108251

202007154

202009139

Brief Summary BTK inhibition and checkpoint blockade are promising classes of therapy for central nervous system (CNS) lymphoma and have demonstrated efficacy with acceptable toxicity. A multidrug approach may carry a higher chance of durable efficacy in this aggressive disease that carries significant morbidity and mortality. Given the poor outcomes and limited options for patients who are not candidates for high-dose methotrexate, the investigators seek to evaluate the combination in this patient population.

202102069

202104077

202105159

202108144

202109079

202203012

202206002

Brief Summary CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024.